Zhengbo Song

机构：Chinese Academy of Sciences, Wenzhou Medical University, Zhejiang Cancer Hospital, Convalife (China), Wuhan Union Hospital, Affiliated Hospital of Hebei University, Union Hospital, University of Chinese Academy of Sciences, Hangzhou Cancer Hospital · ORCID：0000-0002-4817-7775

发表论文 287 篇 · 总被引 4197 次 · h-index 35

代表论文

• Trastuzumab rezetecan, a HER2-directed antibody–drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): phase 2 results from a multicentre, single-arm study (2025 · The Lancet Oncology · 被引 49)
• SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: a multicenter, open-label, phase 1/2 study (2024 · Signal Transduction and Targeted Therapy · 被引 35)
• Expert consensus on the diagnosis and treatment of solid tumors with BRAF mutations (2024 · The Innovation · 被引 13)
• Efficacy and safety of glecirasib in solid tumors with KRAS G12C mutation: A pooled analysis of two phase I/II trials (2025 · 癌症：英文版 · 被引 12)
• Safety and efficacy of ifebemtinib (IN10018) combined with D-1553 in non-small-cell lung cancer (NSCLC) with KRAS G12C mutation: Results from a phase Ib/II study. (2024 · Journal of Clinical Oncology · 被引 8)
• Garsorasib in patients with KRAS G12C-mutated non-small-cell lung cancer: A pooled analysis of phase 1/2 study (2025 · European Journal of Cancer · 被引 3)